metaEvidence - overview

benefit
(statisticaly significant)

benefit (nominaly significant, not statitically demonstrated)

not significant

harm statitically significant

harm not significant

low certainty due to bias


			DCR
mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population
versus placebo plus SoC
	sintillimab plus SoC vs. placebo plus SoC	1	-
versus Standard of Care (SoC)
	cemiplimab vs. Standard of Care (SoC)	1	-
	durvalumab alone vs. Standard of Care (SoC)	1	-